We chose to focus on three putative stem cell markers, SOX2, NES, and CD133, as markers of the cancer stem cell phenotype in order to search for heterogeneity of expression within tumors, interpatient variability in expression patterns, and any possible associations with outcomes or other clinicopathological characteristics. This evidence concerns the gene PROM1 and cancer.